Richard W. Mott - Jan 30, 2023 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Role
Director
Signature
/s/ Lisa Taylor as Attorney-in-fact for Richard Mott
Stock symbol
TMCI
Transactions as of
Jan 30, 2023
Transactions value $
-$2,115,171
Form type
4
Date filed
1/30/2023, 05:30 PM
Previous filing
Jan 19, 2023
Next filing
Feb 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMCI Common Stock Sale -$1.41M -61.5K -4.92% $22.92 1.19M Jan 30, 2023 Direct F1, F2, F3
transaction TMCI Common Stock Sale -$655K -27.4K -2.31% $23.87 1.16M Jan 30, 2023 Direct F1, F3, F4
transaction TMCI Common Stock Sale -$50.1K -2.04K -0.18% $24.58 1.16M Jan 30, 2023 Direct F1, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.4000 to $23.3950 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 Includes 2,295 RSUs.
F4 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.4100 to $24.4000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $24.4150 to $25.1300 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.